Skip to main content
TipRanks
Go Ultimate75% OFF

Xuanzhu Biopharmaceutical Co., Ltd. Class H (2575) AI Stock Analysis

2 Followers
HK:2575

Xuanzhu Biopharmaceutical Co., Ltd. Class H

(HKEX:2575)

Select Model
Rating:43Neutral
Price Target:HKD 7.50▲(0.00% Upside)
Action:reiterated
Date:09/30/26

Xuanzhu Biopharmaceutical scores in the lower band, driven primarily by persistent unprofitability and heavy cash burn: roughly HK$214M of annual operating cash outflow against a small HK$116.9M TTM revenue base and a net margin near -201%. The key offset is an exceptionally clean, essentially debt-free balance sheet with HK$1.50B of equity, providing several years of runway, alongside genuinely improving trends — rapid revenue growth, positive gross margins and sharply narrowing losses. Technicals compound the caution, with the stock well below all major moving averages, negative MACD and very high beta, though deeply oversold stochastic readings hint at a possible short-term bounce. A negative P/E and no dividend leave valuation unsupportive. Execution on revenue scale-up is the decisive variable for any re-rating.

Positive Factors
Revenue GrowthTTM revenue growth of 34.97% indicates expanding commercial traction and provides a stronger base for future operating leverage. If maintained, this momentum can improve the company’s ability to absorb fixed costs and support investment in its biopharmaceutical pipeline.
Negative Factors
Deep Net LossesTTM net margin of approximately negative 201% shows that revenue growth has not translated into earnings and that expenses remain far above a sustainable level. Continued losses weaken internal funding capacity and leave profitability highly dependent on future operating improvement.

Xuanzhu Biopharmaceutical Co., Ltd. Class H (2575) vs. iShares MSCI Hong Kong ETF (EWH)

-100%-75%-50%-25%0%25%50%HK:2575-88.25%EWH+8.61%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 3.94B
Dividend Yield
―
Average Volume (3M)
2.27M
Price to Earnings (P/E)
-15.7
Beta (1Y)
1.83
Revenue Growth
237.19%
EPS Growth
61.28%
Country
Hong Kong
Employees
344
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Xuanzhu Biopharmaceutical Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Xuanzhu Biopharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, production, and commercialization of both small-molecule chemical compounds and large-molecule biopharmaceuticals. The company's primary drug candidates include Co...

Xuanzhu Biopharmaceutical Co., Ltd. Class H Financial Statement Overview

Summary

A mixed profile typical of an early-stage specialty pharma. The balance sheet is the standout strength (score 72): virtually no debt (HK$0.25M) against HK$1.50B of equity, with equity funding roughly 84% of assets after a 2025 capital injection — removing refinancing risk and providing multi-year runway. However, the income statement (36) and cash flow (24) remain weak: TTM revenue of HK$116.9M is dwarfed by a HK$213M operating loss and HK$235M net loss (net margin near -201%), while operations consumed about HK$214M of cash with free cash flow of roughly -HK$214M that re-accelerated in 2025. Encouraging trends — rapid revenue growth off a small base, gross margin turning positive (34.4% TTM) and net losses roughly halving from HK$603M to HK$266M — are offset by a steadily eroding equity cushion (ROE about -15.7%) and the realistic prospect of dilutive fundraising if commercialization does not scale.

Income Statement

36Negative

Balance Sheet

72Positive

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue116.94M56.15M32.63M32.04K00
Gross Profit40.23M21.80M-12.60M-35.52M-30.16M0
EBITDA-185.72M-220.55M-566.36M-295.28M-563.77M-489.29M
Net Income-234.79M-266.26M-603.29M-332.12M-595.70M-566.28M
Balance Sheet
Total Assets1.79B1.83B1.27B1.45B1.63B2.30B
Cash, Cash Equivalents and Short-Term Investments587.30M765.43M294.13M495.15M792.98M1.51B
Total Debt251.80K720.64K1.57M18.79M32.82M36.02M
Total Liabilities292.77M300.83M255.31M232.05M130.75M111.91M
Stockholders Equity1.50B1.53B1.02B1.22B1.50B2.18B
Cash Flow
Free Cash Flow-214.45M-223.60M-105.22M-130.05M-501.15M-597.99M
Operating Cash Flow-213.58M-222.97M-104.67M-128.13M-449.15M-504.75M
Investing Cash Flow103.00M121.20M143.04M49.43M-579.14M59.83M
Financing Cash Flow683.66M675.14M-13.47M-10.94M-14.14M1.05B

Xuanzhu Biopharmaceutical Co., Ltd. Class H Technical Analysis

Technical Analysis SentimentNegative
Last Price7.50

Price Trends

50DMA8.47Negative
100DMA10.19Negative
200DMA23.04Negative

Market Momentum

MACD-0.19Positive
RSI37.72Neutral
STOCH2.11Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2575, the sentiment is Negative. The current price of 7.50 is below the 20-day moving average (MA) of 8.30, below the 50-day MA of 8.47, and below the 200-day MA of 23.04, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 37.72 is Neutral, neither overbought nor oversold. The STOCH value of 2.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2575.

Xuanzhu Biopharmaceutical Co., Ltd. Class H Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:2575 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:3692HK:369275OutperformHKD 196.60B25.1618.26%1.50%24.97%43.23%
HK:9989HK:998956NeutralHKD 13.98B68.451.58%4.24%-1.32%-50.00%
HK:0013HK:001352NeutralHKD 18.74B148.051.43%―-8.55%-96.20%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:6185HK:618551NeutralHKD 10.78B507.830.60%―36.09%―
HK:2575HK:257543NeutralHKD 3.88B-15.74-15.68%―237.19%61.28%
HK:2552HK:255242NeutralHKD 1.98B-17.02-10.61%―83.49%-110.21%

* Healthcare Sector Average

Performance Comparison

-75%-50%-25%0%25%HK:2575HK:0013HK:2552HK:9989HK:3692HK:6185Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:2575 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:2575Xuanzhu Biopharmaceutical Co., Ltd. Class H7.50-55.70-88.13%
HK:0013HUTCHMED (China) Limited21.48-0.44-2.01%
HK:2552Hua Medicine 2.04-1.01-33.28%
HK:9989Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H3.92-1.15-22.66%
HK:3692Hansoh Pharmaceutical Group Company Limited32.42-5.21-13.85%
HK:6185CanSino Biologics, Inc. Class H22.00-17.50-44.30%

Xuanzhu Biopharmaceutical Co., Ltd. Class H Corporate Events

Xuanzhu Biopharmaceutical’s New Bireociclib Indication Included in China’s 2026 NRDL

Nov 15, 2026

Xuanzhu Biopharmaceutical, a biopharmaceutical company developing innovative medicines, said Bireociclib Tablets’ new indication, combined with aromatase inhibitors for first-line treatment of HR+/HER2- advanced breast cancer, has been included in Ch...

Xuanzhu’s Anaprazole Shows Strong Phase III Data in Reflux Esophagitis at UEG Week

Oct 21, 2026

Xuanzhu Biopharmaceutical Co., Ltd. announced that Phase III clinical data for its innovative proton pump inhibitor Anaprazole Sodium Enteric-coated Tablets in reflux esophagitis were presented as a Late-Breaking oral abstract at UEG Week 2026 in Bar...

Xuanzhu Biopharmaceutical Flags Share Price Surge Amid Early-Stage Acquisition Talks

Sep 17, 2026

Xuanzhu Biopharmaceutical Co., Ltd. reported unusual price movements in its Hong Kong-listed H shares, noting a sharp increase in the stock on the day of the announcement. The board stated that, after reasonable inquiries, it was not aware of any und...

Xuanzhu Biopharma INEDs Report No Conflicts With Controlling Shareholders in 2025 Review

Sep 16, 2026

Xuanzhu Biopharmaceutical Co., Ltd., a Hong Kong-listed Chinese biopharma group, has established governance measures to manage potential conflicts of interest with its controlling shareholders, relying on independent non-executive directors to review...

Xuanzhu Biopharma Strikes Thailand Commercial Deal for Breast Cancer Drug Bireociclib

Sep 3, 2026

Xuanzhu Biopharmaceutical has signed a tri-party commercial agreement with Thailand’s Innobic (Asia) and Hong Kong-based ZaoAn International, granting them exclusive rights to commercialise its breast cancer drug Bireociclib in Thailand through 2036,...

Xuanzhu Biopharmaceutical Narrows Interim Loss as Revenue Surges on New Products

Aug 26, 2026

Xuanzhu Biopharmaceutical reported interim revenue of RMB69.4 million for the six months ended June 30, 2026, a 288.1% jump from a year earlier as sales volumes rose on the back of new product launches and broader reimbursement coverage. Operating ex...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 30, 2026